A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.

Simple item page
dc.contributor.authorHuilgol, N Gen_US
dc.contributor.authorNair, C K Ken_US
dc.contributor.authorMerhotra, Pen_US
dc.contributor.authorKagiya, V Ten_US
dc.date.accessioned2005-01-14en_US
dc.date.accessioned2009-06-01T16:13:51Z
dc.date.available2005-01-14en_US
dc.date.available2009-06-01T16:13:51Z
dc.date.issued2005-01-14en_US
dc.description.abstractPURPOSE: To evaluate Tocoferol monoglucoside (TMG), a water soluble vit. E. in a phase I trial, as a radiation protector in those undergoing hemi-body radiation for disseminated disease. MATERIALS AND METHODS: Patients scheduled to receive modified hemi-body radiation were accrued for the study. Patients not only had disseminated skeletal disease but, were heavily pretreated Seven patients were accrued for the study. Patients received 1 and 2 gms of TMG. 30-40 minutes before hemibody radiation. A dose of 600 cGy was delivered on telecobalt equipment at mid plane. Immediate Toxicities were evaluated as well as response to pain. RESULTS: All the seven patients underwent radiation uneventfully. There was no drug related toxicity. Pain relief was adequate. CONCLUSION: Tocoferol monoglucoside an effective antioxidant with no significant acute toxicity, when administered in a dose of 1 or 2 gms per oral route. TMG being water-soluble can have global antioxidant and radio protective effects. This needs further clinical evaluation.en_US
dc.description.affiliationDivision of Radiation Oncology, Nanavati Hospital, Vile Parle (W), Mumbai, India. nagrajh@vsnl.neten_US
dc.identifier.citationHuilgol NG, Nair CK, Merhotra P, Kagiya VT. A phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation. Journal of Cancer Research and Therapeutics. 2005 Jan-Mar; 1(1): 38-40en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/111401
dc.language.isoengen_US
dc.source.urihttps://www.cancerjournal.neten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBreast Neoplasms --radiotherapyen_US
dc.subject.meshGlucosides --adverse effectsen_US
dc.subject.meshHemibody Irradiationen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProstatic Neoplasms --radiotherapyen_US
dc.subject.meshRadiation-Protective Agents --adverse effectsen_US
dc.subject.meshTocopherols --adverse effectsen_US
dc.titleA phase I trial of tocoferol monoglucoside in patients undergoing hemi-body radiation.en_US
dc.typeClinical Trial, Phase Ien_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of Cancer Research and Therapeutics